Helena W Rodbard (Helena Rodbard, H W Rodbard)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 16

Top Topics

Roux En Y Gastric Bypass

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Helena W Rodbard, Katharine Barnard-Kelly, Andreas F H Pfeiffer, Carina Mauersberger, Oliver Schnell, Francesco Giorgino
Practical strategies to manage obesity in type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Helena W Rodbard, Katharine Barnard-Kelly, Andreas F H Pfeiffer, Carina Mauersberger, Oliver Schnell, Francesco Giorgino
Practical strategies to manage obesity in type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Helena W Rodbard, Katharine Barnard-Kelly, Andreas F H Pfeiffer, Carina Mauersberger, Oliver Schnell, Francesco Giorgino
Practical strategies to manage obesity in type 2 diabetes. Diabetes, obesity & metabolism (2024)
Li-Nong Ji, A J Ahmann, Bo Ahrén, M S Capehorn, P Hu, Ildiko Lingvay, W Liu, Helena W Rodbard, Z Shen, C Sorli
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China. Diabetes, obesity & metabolism (2023)
Keith C Ferdinand, Keith C Norris, Helena W Rodbard, Jennifer M Trujillo
Humanistic and Economic Burden of Patients with Cardiorenal Metabolic Conditions: A Systematic Review. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Hiren Patel, Kamlesh Khunti F MedSci, Helena W Rodbard, Harpreet S Bajaj, Ross Bray, Zbigniew Kindracki, Angel Rodríguez
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, obesity & metabolism (2023)
Matthias Blüher, Antonio Ceriello, Melanie Jane Davies, Helena W Rodbard, Naveed Sattar, Oliver Schnell, Elena Tonchevska, Francesco Giorgino
Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come? Endocrinology, diabetes & metabolism 5 (3) (2022)
Helena W Rodbard, Andrea Giaccari, Bertrand Cariou, Satish Garg, Michael J Davies, Kiernan Seth, Sangeeta Sawhney
Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diabetes & vascular disease research 18 (1) (2021)
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro
Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2. Diabetes, obesity & metabolism 22 (11) (2020)
Anne L Peters, Darren K McGuire, Thomas P A Danne, Jake A Kushner, Helena W Rodbard, Ketan K Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies, Pablo Lapuerta
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. Diabetes care 43 (11) (2020)
Helena W Rodbard, Julio Rosenstock, Luis H Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya, null null
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes care 42 (12) (2019)
Thomas P A Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode, Bertrand Cariou, Kelly L Close, Paresh Dandona, Sanjoy Dutta, Eleuterio Ferrannini, Spiros Fourlanos, George Grunberger, Simon R Heller, Robert R Henry, Martin J Kurian, Jake A Kushner, Tal Oron, Christopher G Parkin, Thomas R Pieber, Helena W Rodbard, Desmond Schatz, Jay S Skyler, William V Tamborlane, Koutaro Yokote, Moshe Phillip
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes care 42 (6) (2019)
Joseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael L Wolden, Helena W Rodbard
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes. Diabetes, obesity & metabolism 21 (4) (2019)
Liana K Billings, Ankur Doshi, Didier Gouet, Alejandra Oviedo, Helena W Rodbard, Nikolaos Tentolouris, Randi Grøn, Natalie Halladin, Esteban Jodar
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes care 41 (5) (2018)
Martin Haluzík, Greg Fulcher, Thomas R Pieber, Lars Bardtrum, Deniz Tutkunkardas, Helena W Rodbard
The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes, obesity & metabolism 20 (7) (2018)
Helena W Rodbard, Devjit Tripathy, Maricela Vidrio Velázquez, Marek Demissie, Søren C Tamer, Milivoj Piletič
Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes, obesity & metabolism 19 (10) (2017)